Description
Dose-response analysis of melatonin treatment on prostate cancer cell viability and lipid droplet formation. Increasing MLT concentrations appear associated with reduced intracellular lipid accumulation.
Figure 3
ChartSource Paper
Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.Cite This Figure
![Figure 3: Dose-response analysis of melatonin treatment on prostate cancer cell viability and lipid droplet formation. Increasing MLT concentrations appear associated with reduced intracellular lipid accumulation.]() > Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)
<figure> <img src="" alt="Dose-response analysis of melatonin treatment on prostate cancer cell viability and lipid droplet formation. Increasing MLT concentrations appear associated with reduced intracellular lipid accumulation." /> <figcaption>Figure 3. Dose-response analysis of melatonin treatment on prostate cancer cell viability and lipid droplet formation. Increasing MLT concentrations appear associated with reduced intracellular lipid accumulation.<br> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption> </figure>